

West Virginia Marketplace

Policy Updates January 2018

- Reimbursement Policies
- Medical Policies

The following policies are effective January 1, 2018

WV-EXCP-0069



AT CARESOURCE, WE LISTEN TO OUR HEALTH PARTNERS, AND WE STREAMLINE OUR BUSINESS PRACTICES TO MAKE IT EASIER FOR YOU TO WORK WITH US.

We have worked to create a predictable cycle for releasing medical and reimbursement policies, so you know what to expect. Check back each month for a consolidated network notification of medical and reimbursement policy updates from CareSource.

HOW TO USE THIS NETWORK NOTIFICATION:

- Reference the [Table of Contents](#) and click on the policy title to navigate to the corresponding policy summary.
- The summary will indicate the effective date and impacted plans for each policy.
- Within the summary, click on the hyperlinked policy title to open the webpage with the full policy.

FIND OUR POLICIES ONLINE

To access all CareSource policies, visit **CareSource.com** and click on “Health Partner Policies” under the “Provider Resources” menu.

CLAIMS AND APPEALS

As indicated in the applicable Health Partner Manual, if you do not agree with the decision of a processed claim, you will have 365 days from the date of service or discharge to file an appeal. Please submit your appeal through the Provider Portal or in writing. For detailed instructions, please consult your applicable Health Partner Manual.

TABLE OF CONTENTS

POLICY TITLE	PAGE
<u>Long Acting Reversible Contraceptives – WV MPP PY-0346</u>	4
<u>Medical Necessity Determinations – WV MPP AD-0050</u>	7
<u>Screening and Surveillance for Colorectal Cancer (Medical Policy) – WV MPP MM-0199</u>	8
<u>Screening and Surveillance for Colorectal Cancer (Reimbursement Policy) – WV MPP PY-0407</u>	10

POLICY NAME	POLICY TYPE	EFFECTIVE DATE	PLANS	SUMMARY	IMPACT
Long Acting Reversible Contraceptives –PY-0346	Reimbursement	01/01/2017	Marketplace	<p>CareSource recognizes Long Acting Reversible Contraceptive methods (LARCs) to be among the most effective contraception available to our members in assisting with their reproduction and family planning decisions.</p> <p>While LARCs do not prevent or reduce the likelihood or danger of sexually transmitted infections or their transmission, they do allow sexually active members a greater degree of certainty with a better percentage of success, and generally, less frequent medical maintenance and intervention, than other available contraceptive methods.</p>	<p>Prior authorization is not required for the long acting reversible contraceptives (LARCs) covered by this policy.</p> <p>Services covered under this policy include:</p> <ul style="list-style-type: none"> • Management and evaluation (office) visits and consultations for the purpose of providing LARCs; • Health education and counseling visits for the purpose of providing LARCs; • Medical/surgical services/procedures provided in association with the provision of LARCs; • Laboratory tests and procedures provided in association with the provision of LARCs; • Drugs administered as part of LARCs; and supplies provided as part of LARCs; • Implantable contraceptive capsules and intrauterine devices (see also, the “Long Acting Reversible Contraceptives (LARCs)” policy); • Diaphragms and cervical caps; • Injectable contraceptives; • Hormone patch contraceptives; and, (continued)

POLICY NAME	POLICY TYPE	EFFECTIVE DATE	PLANS	SUMMARY	IMPACT
Long Acting Reversible Contraceptives –PY-0346 (Continued)	Reimbursement	01/01/2017	Marketplace		<ul style="list-style-type: none"> • Male and female condoms (per visit and annual limits apply to these). <p>Covered Settings and Timing for the insertions or removals of LARCs are:</p> <ul style="list-style-type: none"> • Insertion or removal of a LARC may be performed and billed in conjunction with an initial or annual comprehensive visit, a follow up comprehensive medical visit, a brief medical visit, or a supply visit by a member to a qualifying provider participant, as detailed in the corresponding CareSource “Family Planning” reimbursement policy. • CareSource will also reimburse providers for LARCs inserted immediately postpartum in a hospital setting, in addition to and separately from the Diagnostic Related Group reimbursement process for the hospital. In this circumstance, if the provider uses one of the following implantable devices, it must be inserted within ten minutes of birth to decrease the likelihood of expulsion of the device: <ul style="list-style-type: none"> ○ J7297 - Levonorgestrel-releasing intrauterine contraceptive system (Liletta), 52mg; ○ J7298 - Levonorgestrel-releasing intrauterine contraceptive system (Mirena), 52mg; ○ J7300 - Intrauterine copper contraceptive; or, ○ J7301 - Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5mg. <p><i>(continued)</i></p>

POLICY NAME	POLICY TYPE	EFFECTIVE DATE	PLANS	SUMMARY	IMPACT
Long Acting Reversible Contraceptives –PY-0346 (Continued)	Reimbursement	01/01/2017	Marketplace		<p>CareSource will reimburse the following providers for the insertion and removal of implantable contraceptive capsules and intrauterine devices, after each has been trained in accordance with the manufacturer’s guidelines:</p> <ul style="list-style-type: none"> • Physicians; • Nurse practitioners; • Midwives; and, • Physicians’ assistants. <p>Documentation of this training must be maintained in the provider’s personnel or training record.</p> <p>The insertion, management and monitoring, and removal of these capsules must be performed in compliance with all manufacturer’s recommendations.</p> <p>Insertions are limited to once per member within any three year period.</p> <p>Claims not meeting the necessary criteria as described in the policy document will be denied.</p>

POLICY NAME	POLICY TYPE	EFFECTIVE DATE	PLANS	SUMMARY	IMPACT
Medical Necessity Determinations –AD-0050	Administrative	01/01/2017	Marketplace	<p>If nationally- recognized evidence-based criteria or CareSource-developed medical policy statement pertinent to the requested service is available, it is to be used as the basis for decision-making, and this policy is not applicable.</p> <p>CareSource will follow policies and procedures to meet relevant timelines and notification requirements as appropriate for all urgent and non-urgent requests.</p>	<p>When a request for a service, procedure or product is subject to medical necessity review, the CareSource reviewer will determine based on the following hierarchy:</p> <ul style="list-style-type: none"> • Benefit contract language; • Federal or State regulation; • CareSource Medical Policy Statements; • Nationally-accepted evidence-based clinical guideline (MCG). <p>If the requested service is not addressed by the above hierarchy of review, the CareSource medical or behavioral health reviewer will use professional judgment in the absence of evidence-based methodology to determine appropriate resources or other clinical best practice guidelines identified by the reviewer, which may be deemed applicable to the unique clinical circumstances of the member.</p> <p>Please refer to the policy for a list of potential resources (which is not intended to be wholly inclusive).</p> <p>If required, providers must submit their prior authorization number, their claim form, as well as appropriate HCPCS and/or CPT codes along with appropriate modifiers in accordance with CMS.</p> <p>Claims not meeting the necessary criteria as described in the policy document will be denied. (</p>

POLICY NAME	POLICY TYPE	EFFECTIVE DATE	PLANS	SUMMARY	IMPACT
Screening and Surveillance for Colorectal Cancer – MM-0199	Medical	01/01/2017	Marketplace	<p>The purpose of the new Screening and Surveillance for Colorectal Cancer West Virginia Marketplace Plans medical policy is to provide health partners with medical necessity and policy rationale information consistent with the most up to date evidence based medical literature regarding screening and surveillance for colorectal cancer services.</p>	<p>CareSource will cover, as medically necessary, the following preventive screening tests for members at average risk for CRC between 50-75 years of age (ending at 76th birthday):</p> <ul style="list-style-type: none"> • Screening Colonoscopy every 10 years • Flexible sigmoidoscopy every 5 years in combination with FOBT or FIT every 3 years • DCBE every 5 years • FOBT or FIT yearly • Multi-targeted Stool DNA (Cologuard): CareSource will cover, as medically necessary, once every 3 years for members as outlined in this policy <p>CareSource will cover, as medically necessary, preventive screening tests for members at high risk, including:</p> <ul style="list-style-type: none"> • A first degree relative (sibling, parent or child) who has had colorectal cancer or an adenomatous polyp • A family history of familial adenomatous polyposis • Inherited risk through a family history of hereditary nonpolyposis colorectal cancer (HNPCC) or familial adenomatous polyposis (FAP) • A personal history of adenomatous polyps • A personal history of colorectal cancer • A personal history of inflammatory bowel disease including Crohn’s disease or ulcerative colitis

POLICY NAME & NUMBER	POLICY TYPE	EFFECTIVE DATE	PLANS	SUMMARY	IMPACT
Screening and Surveillance for Colorectal Cancer – MM-0199 (Continued)	Medical	12/1/2017	Marketplace		<p>Surveillance in members following resection of CRC:</p> <ul style="list-style-type: none"> ○ Although individuals with adenomatous polyps or CRC require surveillance following removal and/or resection the USPSTF did not address evidence for the effectiveness of any particular regimen ○ The USPSTF did not specifically review the evidence on screening in high risk populations, but indicate professional organization recommendations for more frequent and earlier screening for high risk patients with a family history of colorectal cancer (a first-degree relative with early-onset colorectal cancer or multiple first-degree relatives with the disease) ○ For patients under the age of 50 considered to be at high risk CareSource requires the provider submit documentation of family history or other risk indicators <p>CT Colonography:</p> <ul style="list-style-type: none"> • The USPSTF concludes that the effectiveness of CT colonography is limited by studies that only define test characteristics. CareSource considers the use of CT colongraphy for screening purpose of CRC to be unproven for improving health outcomes and not medically necessary

POLICY NAME & NUMBER	POLICY TYPE	EFFECTIVE DATE	PLANS	SUMMARY	IMPACT
Screening and Surveillance for Colorectal Cancer – PY-0407	Reimbursement	01/01/2017	Marketplace	<p>The Screening and Surveillance for Colorectal Cancer reimbursement policy will reimburse participating providers for medically necessary screening and surveillance for colorectal cancer services according to Screening and Surveillance for Colorectal Cancer medical policy MM-0199 criteria.</p>	<p>CareSource does not require prior authorization for screening and diagnostic colonoscopies for participating providers.</p> <p>CareSource reimburses for colonoscopies and other screening and surveillance services based on the criteria found in the Screening and Surveillance for Colorectal Cancer medical policy MM-0199</p> <p>When billing for screening and surveillance services for colorectal cancer, providers should use the appropriate CPT/HCPCS codes and modifiers, if applicable.</p>